Comprehensive evaluation of clinical prognostic parameters in a real-world cohort of 812 patients with multiple myeloma

Abstract

Objectives

Multiple myeloma (MM) is an incurable malignancy with heterogeneous clinical manifestations and prognoses. The existing staging systems offer assistance in prognosis determination, yet their accuracy in the real-world context is limited, and numerous crucial parameters have been disregarded. Comprehensive exploration of prognostic value parameters for MM patients in the real world is of paramount significance.

Methods

In this study, 812 newly diagnosed MM patients treated with standard first-line therapy at Zhongshan Hospital Fudan University from January 2010 to April 2021 were enrolled, representing one of the largest MM cohorts in China. Among them, 703 patients did not receive transplantation (527 in the training set and 176 in the validation set), and 109 patients underwent transplantation. Forty-three baseline parameters encompassing clinical, laboratory, and pathological features were incorporated. Univariate and multivariate Cox analyses were conducted to screen the most prognostically significant parameters.

Results

The results revealed that ten parameters, including ECOG score, extramedullary lesions, platelet count, reticulocyte count, anion gap, hypercalcemia, complement C3, β2-microglobulin, cytogenetics, and interleukin-2 receptor, were of the greatest prognostic value. These parameters include some integrated into current mainstream staging systems and many previously overlooked. A risk scoring system was developed using these ten parameters, demonstrating relatively high accuracy.

Conclusion

This research comprehensively evaluated the baseline disease characteristics of a wide range of MM patients, validated and identified the clinical significance of various parameters, providing new evidence for accurate prognosis determination of patients.

Keywords

Multiple myeloma / Prognosis / Real-world study / Clinical parameters

References

[1] RajkumarSV. Treatment of multiple myeloma. Nat Rev Clin Oncol, 2011, 88479-491.

[2] International Myeloma Working G. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. Jun 2003;121(5):749–57.

[3] SawyerJR. The prognostic significance of cytogenetics and molecular profiling in multiple myeloma. Cancer Genet, 2011, 20413-12.

[4] ChngWJ, DispenzieriA, ChimCS, et al. . IMWG consensus on risk stratification in multiple myeloma. Leukemia, 2014, 282269-277.

[5] AndersonLDJr. More key players in the game for myeloma prognosis and therapy. Br J Haematol, 2022, 19661288-1289.

[6] D'AgostinoM, CairnsDA, LahuertaJJ, et al. . Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project. J Clin Oncol, 2022, 40293406-3418.

[7] ShangY, JinY, LiuH, et al. . Evaluation of prognostic staging systems of multiple myeloma in the era of novel agents. Hematol Oncol, 2022, 402212-222.

[8] Padala SA, Barsouk A, Barsouk A, et al. Epidemiology, Staging, and Management of Multiple Myeloma. Med Sci (Basel). Jan 20 2021;9(1)https://doi.org/10.3390/medsci9010003

[9] MikhaelJR, DingliD, RoyV, et al. . Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013. Mayo Clin Proc, 2013, 884360-376.

[10] Avet-LoiseauH. Ultra high-risk myeloma. Hematology Am Soc Hematol Educ Program, 2010, 2010: 489-493.

[11] CorreJ, MunshiNC, Avet-LoiseauH. Risk factors in multiple myeloma: is it time for a revision?. Blood, 2021, 137116-19.

[12] van Buuren S, Groothuis-Oudshoorn K. mice: Multivariate Imputation by Chained Equations in R. J Statist Softw. 12/12 2011;45(3):1 - 67. https://doi.org/10.18637/jss.v045.i03

[13] Gonzalez-CalleV, SlackA, KeaneN, et al. . Evaluation of Revised International Staging System (R-ISS) for transplant-eligible multiple myeloma patients. Ann Hematol, 2018, 9781453-1462.

[14] Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538–48. https://doi.org/10.1016/S1470-2045(14)70442-5

[15] GreippPR, San MiguelJ, DurieBG, et al. . International staging system for multiple myeloma. J Clin Oncol, 2005, 23153412-3420.

[16] SchoutenTJ, DaamenLA, DorlandG, et al. . Nationwide Validation of the 8th American Joint Committee on Cancer TNM Staging System and Five Proposed Modifications for Resected Pancreatic Cancer. Ann Surg Oncol, 2022, 2995988-5999.

[17] HariPN, ZhangMJ, RoyV, et al. . Is the International Staging System superior to the Durie-Salmon staging system? A comparison in multiple myeloma patients undergoing autologous transplant. Leukemia, 2009, 2381528-1534.

[18] Jimenez-Segura R, Rosinol L, Cibeira MT, et al. Paraskeletal and extramedullary plasmacytomas in multiple myeloma at diagnosis and at first relapse: 50-years of experience from an academic institution. Blood Cancer J. Sep 16 2022;12(9):135. https://doi.org/10.1038/s41408-022-00730-5

[19] Bansal R, Rakshit S, Kumar S. Extramedullary disease in multiple myeloma. Blood Cancer J. Sep 29 2021;11(9):161. https://doi.org/10.1038/s41408-021-00527-y

[20] ZagouriF, KastritisE, ZomasA, et al. . Hypercalcemia remains an adverse prognostic factor for newly diagnosed multiple myeloma patients in the era of novel antimyeloma therapies. Eur J Haematol, 2017, 995409-414.

[21] ZanwarS, KumarS. Disease heterogeneity, prognostication and the role of targeted therapy in multiple myeloma. Leuk Lymphoma, 2021, 62133087-3097.

[22] GroenRW, NoortWA, RaymakersRA, et al. . Reconstructing the human hematopoietic niche in immunodeficient mice: opportunities for studying primary multiple myeloma. Blood, 2012, 1203e9-e16.

[23] KatodritouE, TerposE, ZervasK, et al. . Hypochromic erythrocytes (%): a reliable marker for recognizing iron-restricted erythropoiesis and predicting response to erythropoietin in anemic patients with myeloma and lymphoma. Ann Hematol, 2007, 865369-376.

[24] SonneveldP, Avet-LoiseauH, LonialS, et al. . Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. Blood, 2016, 127242955-2962.

[25] Biran N, Jacobus S, Vesole DH, et al. Outcome with lenalidomide plus dexamethasone followed by early autologous stem cell transplantation in patients with newly diagnosed multiple myeloma on the ECOG-ACRIN E4A03 randomized clinical trial: long-term follow-up. Blood Cancer J. Sep 2 2016;6(9):e466. https://doi.org/10.1038/bcj.2016.68

[26] AinD, ShaikhT, ManimalaS, GhebrehiwetB. The role of complement in the tumor microenvironment. Fac Rev, 2021, 10: 80.

[27] WangL, WangJH, LiuWJ, et al. . High level of soluble interleukin-2 receptor in serum predicts treatment resistance and poor progression-free survival in multiple myeloma. Ann Hematol, 2017, 96122079-2088.

[28] JiangF, LiuH, PengF, et al. . Complement C3a activates osteoclasts by regulating the PI3K/PDK1/SGK3 pathway in patients with multiple myeloma. Cancer Biol Med, 2021, 183721-733.

[29] Luczkowska K, Rutka M, Roginska D, et al. The Potential Role of Proinflammatory Cytokines and Complement Components in the Development of Drug-Induced Neuropathy in Patients with Multiple Myeloma. J Clin Med. Oct 4 2021;10(19)https://doi.org/10.3390/jcm10194584

[30] Fiorenza AM, Branchi A, Cardena A, Molgora M, Rovellini A, Sommariva D. Serum cholesterol levels in patients with cancer. Relationship with nutritional status. Int J Clin Lab Res. 1996;26(1):37–42. https://doi.org/10.1007/BF02644772

Funding

Science and Technology Innovation Plan Of Shanghai Science and Technology Commission(21YF1406300)

Natural Science Foundation of Shanghai Municipality(22ZR1411400)

Youth Foundation of Zhongshan hospital Fudan University(2021ZSQNN61)

RIGHTS & PERMISSIONS

The Author(s)